Three key elements to precision medicine are stratification by risk, detection of pathophysiological processes as early as possible (even before clinical presentation), and alignment of mechanism of action of intervention(s) with an individual's molecular driver(s) of disease. Used for decades in the management of some rare diseases and now gaining broad currency in cancer care, a precision medicine approach is beginning to be adapted to cognitive impairment and dementia. This review focuses on the application of precision medicine to address the clinical and biological complexity of two common neurodegenerative causes of dementia: Alzheimer disease and Parkinson disease.
Bibliographical noteFunding Information:
Supported by NIH grants P50 AG005136 (T.J.M., C.D.K., T.J.G.), P50 NS062684 (T.J.M., C.P.Z., J.F.Q., T.J.G.), R01 AG042437 (P.K.C.), R01 NS065070 (C.P.Z.), and U01 AG006781 (E.B.L.); the Office of Research and Development Medical Research Service, Department of Veterans Affairs (C.P.Z., J.F.Q.); and the Nancy and Buster Alvord Endowment (T.J.M.).
© Copyright 2016 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.